Table 3.
Cox multivariate regression analyses of factors associated with PFS of patients.
| Variables | HR (95% CI) | p- Value |
|---|---|---|
| Number of brain metastases (≥3 vs. 1–2) | 1.405 (0.389–5.078) | 0.604 |
| Number of visceral metastases (including brain, ≥3 vs. 1–2) | 6.255 (0.767–51.000) | 0.087 |
| Location of brain metastases (subtentorial vs. supratentorial) | 6.222 (1.264–30.638) | 0.025 |
| Location of brain metastases (supratentorial and subtentorial vs. supratentorial) | 5.863 (1.051–32.717) | 0.044 |
| Previous brain radiotherapy (yes vs. no) | 3.268 (1.018–10.493) | 0.047 |
| Prior treatment by TKIs (yes vs. no) | 1.316 (0.308–5.616) | 0.711 |
| Treatment lines for pyrotinib in metastatic setting (≥3 vs. 1–2) | 4.949 (1.071–22.880) | 0.041 |
| Combined with trastuzumab (yes vs. no) | 0.380 (0.129–1.117) | 0.079 |
Model was adjusted by hormone receptors, prior exposure to endocrine therapy, lung metastasis, and liver metastases. Visceral metastases referred to lung, liver, brain, pleural, and peritoneal involvement.
CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; TKIs, tyrosine kinase inhibitors.